A COA-affiliated Oncology Pharmacy Webinar: Advancing AML Care: Equipping Pharmacists to Implement Menin Inhibitor Therapies with Precision

Program Description

Acute myeloid leukemia (AML) is a rapidly progressing hematologic cancer that primarily affects older adults. Approximately 50% of all patients with AML who achieve a first remission will eventually relapse, and this rate is significantly higher in older adults, as many are unable to tolerate the intensive chemotherapy and consolidation therapy strategies. In recent years, the treatment landscape has transitioned from "7+3" chemotherapy to a complex landscape of molecularly targeted therapies, driven by molecular markers. The rapid approval of targeted agents like FLT3, IDH1/2, and menin inhibitors has transformed AML into a disease managed as much in the home as in the clinic. Yet, this approach also has introduced significant challenges surrounding next-generation sequencing results, adverse effect management, and appropriate medication use. This webinar will explore the pathophysiology of AML, with a focus on how menin inhibitors may be integrated into treatment regimens based on clinical trial data in the frontline, relapsed/refractory, and post-transplant AML settings. Expert faculty will discuss strategies to prevent and manage menin inhibitor-related adverse effects. Best practices to support the multidisciplinary team, share patient education, and implement community oncology pharmacy logistics will also be presented.

Target audience: Oncology Pharmacist
Type of activity: Application
Release date: March 20, 2026
Expiration date: March 20, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.25 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the mechanism of action of menin inhibitors and the therapeutic rationale in acute myeloid leukemia (AML)
• Evaluate pivotal efficacy and safety data of commercially available and investigational menin inhibitors from clinical trials in AML
• Identify strategies for monitoring and managing adverse effects associated with commercially available and investigational menin inhibitors for the treatment of AML
• Develop pharmacist-led strategies to integrate menin inhibitors into AML care pathways, with attention to sequencing, adherence, and supportive care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-26-017-H05-P. The activity is available for CE credit through March 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Anthony J. Perissinotti, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: AbbVie, Amgen, Servier, Syndax

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms